CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neovacs SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neovacs SA
3-5, Impasse Reille
Phone: +33 153109300p:+33 153109300 PARIS, 75014  France Ticker: ALNEVALNEV
Business Summary
Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
6289 Services allied with the exchange of securities or commodities

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer HugoBrugiere 5/16/2020 5/16/2020
Chief Operating Officer, Chief Scientific Officer VincentSerra 54 5/16/2020 2/20/2019
Vice President - Pharmaceutical Affairs BernardFanget 1/1/2020 7/1/2005
5 additional Officers and Directors records available in full report.

Business Names
Business Name
0LW
0W8U
ALNEV
Neovacs, Inc.

General Information
Number of Employees: 22 (As of 6/30/2024)
Outstanding Shares: 9,336,740 (As of 6/30/2024)
Stock Exchange: EPA
Fax Number: +33 153109303


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024